Munich (Germany) – August 29, 2013 – BICOLL Group announces today the successful application
of its technology for the identification of ligands of a specific orphan target. As described in a new
publication in the Journal of Biomolecular Screening, a class of potent and bioavailable RAR-related
orphan receptor alpha (RORα) agonists has been identified in a plant extract library from BICOLL.
The findings were generated in collaboration with Genfit, a biopharmaceutical company at the
forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment
of cardiometabolic and associated disorders. The successful joint program demonstrates the general
effectiveness of BICOLL’s small molecule approach on orphan targets as a case study. Indeed, the use
of BICOLL’s technology of fractionated plant extracts (Profiles™) has led to a timely identification of
potent ligands and enabled target validation studies in vivo within a period of 9-months from the start
of the initial screening.